Development of Tailless Homologue Receptor (TLX) Agonist Chemical Tools

The human tailless homologue receptor (TLX) is a ligand-activated transcription factor acting as a master regulator of neural stem cell homeostasis. Despite its promising potential in neurodegenerative disease treatment, TLX ligands are rare but required to explore phenotypic effects of TLX modulation and for target validation. We have systematically studied and optimized a TLX agonist scaffold obtained by fragment fusion. Structural modification enabled the development of two TLX agonists endowed with nanomolar potency and binding affinity. Both exhibited favorable chemical tool characteristics including high selectivity and low toxicity. Most notably, the TLX agonists comprise different scaffolds and display high chemical diversity, enabling their use as a set for target identification and validation studies.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2024-09-05
DOI
https://doi.org/10.1021/acs.jmedchem.4c01443
Citations
4
Primary Topic
Chemical Synthesis and Analysis
Type
article
Field-Weighted Citation Impact
0.94

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of Tailless Homologue Receptor (TLX) Agonist Chemical Tools

Isabelle Meijer, Minh Sai, Emily C. Hank, Julian A. Marschner et al.
4 citations
Journal of Medicinal Chemistry
Chemical Synthesis and Analysis
0.94
article

Development of Tailless Homologue Receptor (TLX) Agonist Chemical Tools

Isabelle Meijer, Minh Sai, Emily C. Hank, Julian A. Marschner, Daniel Merk, Till Kasch
article en
4 citations

Abstract

The human tailless homologue receptor (TLX) is a ligand-activated transcription factor acting as a master regulator of neural stem cell homeostasis. Despite its promising potential in neurodegenerative disease treatment, TLX ligands are rare but required to explore phenotypic effects of TLX modulation and for target validation. We have systematically studied and optimized a TLX agonist scaffold obtained by fragment fusion. Structural modification enabled the development of two TLX agonists endowed with nanomolar potency and binding affinity. Both exhibited favorable chemical tool characteristics including high selectivity and low toxicity. Most notably, the TLX agonists comprise different scaffolds and display high chemical diversity, enabling their use as a set for target identification and validation studies.

Journal of Medicinal ChemistryVol. 67(18)
Ludwig-Maximilians-Universität München (DE)
H2020 European Research Council
Zero hunger
Openalex Percentile: Top 25%
Chemical Synthesis and Analysis
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Development of Tailless Homologue Receptor (TLX) Agonist Chemical Tools — Isabelle Meijer, Minh Sai, et al. · Journal of Medicinal Chemistry (2024) | TGRS Research Map | TGRS